Advertisement
BMY vs SNY
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Sanofi (SNY) Stock Comparison
Key Takeaways
- BMY has significantly outperformed SNY year-to-date (YTD, year-to-date), with gains around 12% compared to SNY's near-flat performance.
- Both stocks offer attractive dividends exceeding 4%, with SNY at approximately 5% and BMY at 4.3%.
- BMY's lower price-to-earnings (P/E) ratio of about 17 suggests better relative valuation than SNY's 20.
- Recent weeks show BMY in a stronger uptrend amid growth drug sales rises, while SNY benefits from immunology approvals but trails in momentum.
- Market caps are closely matched around $115-120 billion, reflecting similar scale in the pharmaceuticals sector.
- Pipeline catalysts in oncology and immunology position both for defensive growth in volatile markets.
Introduction
Bristol-Myers Squibb (BMY) and Sanofi (SNY) represent two pillars of the global pharmaceuticals industry, focusing on oncology, immunology, and vaccines. This comparison is particularly relevant for investors seeking defensive healthcare exposure with growth potential amid economic uncertainty. Traders monitoring relative performance may find value in their divergent momentum, high dividends, and pipeline developments. Both companies navigate patent challenges while advancing innovative therapies, offering insights into sector rotation and value opportunities in recent market activity.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) is a leading biopharmaceutical firm specializing in oncology, hematology, immunology, and cardiovascular treatments, with key products like Opdivo and Eliquis. In recent market activity, the stock has exhibited resilience, trading near its 52-week high of around $63 within a range of $43-$63. Year-to-date gains exceed 12%, driven by a successful transition where growth medicines now comprise 55% of revenue, up 17% in sales. Sentiment has strengthened on pipeline momentum and collaborations in oncology, supporting an uptrend above key moving averages despite broader sector pressures.
SNY Overview and Recent Performance
Sanofi (SNY), a French multinational, develops therapies in immunology, rare diseases, neurology, oncology, and vaccines, highlighted by Dupixent and pediatric immunizations. The stock has shown short-term gains of about 6% over recent weeks, within a 52-week range of $43-$56, but remains relatively flat YTD. Positive sentiment stems from expanded approvals for Dupixent in urticaria and other areas, alongside collaborations, though longer-term performance lags amid revenue dynamics. Neutral momentum indicators reflect steady accumulation without aggressive upside.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the top 25 performers from over 350 AI trading bots, curated for current market conditions across sectors like semiconductors, energy, and finance. These bots deliver impressive stats, including annualized returns from +15% to +168%, win rates of 54%-88%, profit factors up to 11.7, and profit-to-drawdown ratios reaching 22. Each employs unique strategies—such as trend-following, swing trading, or multi-agent baskets—across 1-25 tickers with varying timeframes from 1 day to 55 days. While none currently feature BMY or SNY, they highlight AI's edge in dynamic trading. Explore these high-performing bots to enhance your strategy in today's markets.
Head-to-Head Comparison
Both BMY and SNY operate diversified models in pharmaceuticals, with BMY emphasizing U.S.-centric oncology and hematology, while SNY balances vaccines and European immunology. Growth drivers differ: BMY's newer portfolio fuels revenue acceleration, contrasting SNY's reliance on Dupixent expansions. Recent momentum favors BMY with superior YTD returns and uptrend stability versus SNY's neutral short-term gains. Risk factors include patent expirations for both, though BMY's higher return on equity (ROE, return on equity) around 40% edges out SNY. Sector exposure overlaps in healthcare defensives, but market sentiment tilts toward BMY's catalysts.
Tickeron AI Verdict
Tickeron's AI currently leans toward BMY over SNY, based on stronger trend consistency, YTD outperformance, and pipeline-driven stability. While SNY shows promise in approvals, BMY's relative positioning suggests higher probability of near-term upside in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and SNY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 2 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 2 green, 3 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 2 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 5 bearish.
- SNY’s TA Score: 2 bullish, 8 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -5.10% price change this week, while SNY (@Pharmaceuticals: Major) price change was -3.92% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
SNY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | SNY | BMY / SNY | |
| Capitalization | 110B | 101B | 109% |
| EBITDA | 15B | 8.52B | 176% |
| Gain YTD | 2.339 | -7.701 | -30% |
| P/E Ratio | 15.13 | 18.43 | 82% |
| Revenue | 48.5B | 47.4B | 102% |
| Total Cash | 10.5B | 5.54B | 189% |
| Total Debt | 46.4B | 20B | 232% |
BMY | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 10 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 25 | 71 | |
PRICE GROWTH RATING 1..100 | 58 | 60 | |
P/E GROWTH RATING 1..100 | 67 | 41 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (3) in the Pharmaceuticals Major industry is in the same range as BMY (18). This means that SNY’s stock grew similarly to BMY’s over the last 12 months.
SNY's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as BMY (100). This means that SNY’s stock grew similarly to BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNY (71). This means that BMY’s stock grew somewhat faster than SNY’s over the last 12 months.
BMY's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that BMY’s stock grew similarly to SNY’s over the last 12 months.
SNY's P/E Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as BMY (67). This means that SNY’s stock grew similarly to BMY’s over the last 12 months.
| BMY | SNY | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 55% | 20 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 61% | 3 days ago 54% |
| Momentum ODDS (%) | 3 days ago 58% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 55% | 3 days ago 47% |
| TrendWeek ODDS (%) | 3 days ago 56% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 43% |
| Advances ODDS (%) | 9 days ago 54% | 9 days ago 50% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 49% |
| BollingerBands ODDS (%) | 3 days ago 58% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 55% |
Advertisement
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then NVS could also see price increases.